SYRE logo

SYRE
Spyre Therapeutics Inc

2,156
Mkt Cap
$6.26B
Volume
1.11M
52W High
$78.80
52W Low
$13.93
PE Ratio
-31.17
SYRE Fundamentals
Price
$73.50
Prev Close
$72.11
Open
$71.83
50D MA
$63.94
Beta
1.78
Avg. Volume
1.42M
EPS (Annual)
-$1.98
P/B
11.25
Rev/Employee
$0.00
$1,497.78
Loading...
Loading...
News
all
press releases
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks
Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE
24-7 Market News
News Placeholder
More News
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at Citigroup
Citigroup upped their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a "buy" rating in a research note on Wednesday...
MarketBeat
News Placeholder
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of...
MarketBeat
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average...
MarketBeat
News Placeholder
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 12,500 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average price...
MarketBeat
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3% - Here's Why...
MarketBeat
News Placeholder
Pictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYRE
Pictet Asset Management Holding SA cut its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 11.8% during the 4th quarter, according to the company in its most recent Form...
MarketBeat
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Sets New 1-Year High - Still a Buy...
MarketBeat
News Placeholder
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Spyre Therapeutics, Inc. $SYRE
Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 55.0% in the fourth quarter, according to the company in its most...
MarketBeat
News Placeholder
Wall Street Zen Downgrades Spyre Therapeutics (NASDAQ:SYRE) to Sell
Wall Street Zen lowered Spyre Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday...
MarketBeat
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available